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Abstract: Single nucleotide polymorphisms (SNPs) are important markers which can be 
used in association studies searching for susceptible genes of complex diseases. High-
throughput methods are needed for SNP genotyping in a large number of samples. In this 
study, we applied polyacrylamide gel-based microarray combined with dual-color 
hybridization for association study of four BDNF polymorphisms with autism. All the 
SNPs in both patients and controls could be analyzed quickly and correctly. Among four 
SNPs, only C270T polymorphism showed significant differences in the frequency of the 
allele (χ
2 = 7.809,  p = 0.005) and genotype (χ
2 = 7.800,  p = 0.020). In the haplotype 
association analysis, there was significant difference in global haplotype distribution 
between the groups (χ
2 = 28.19，p = 3.44e-005). We suggest that BDNF has a possible 
role in the pathogenesis of autism. The study also show that the polyacrylamide gel-based 
microarray combined with dual-color hybridization is a rapid, simple and high-throughput 
method for SNPs genotyping, and can be used for association study of susceptible gene 
with disorders in large samples. 
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1. Introduction 
 
Single nucleotide polymorphisms (SNPs) are the most frequently occurring genetic variation in the 
human genome, with the total number reported in public SNP databases currently exceeding nine 
million [1,2]. SNPs are important markers which can account for phenotypic diversity, influencing risk 
of certain disease, and variable response to drugs and the environment. Genetic association studies 
utilizing SNP markers are expected to allow identification of genetic factors responsible for complex 
diseases that will facilitate early diagnosis, prevention, prognosis and, possibly, treatment of human 
diseases [3,4]. Due to the large number of SNPs, methods that allow high-throughput, cost-effective 
and fast detection are needed. A variety of techniques have been developed to type SNPs in a high-
throughput fashion [5-7], DNA microarray is one of the high-throughput platform for SNPs analysis. 
DNA microarrays allow us to acquire abundant information at once. A significant advantage of 
performing assays in microarray formats is that the costs of genotyping are reduced, because many 
SNPs are analyzed simultaneously, and the reaction volume employed on the microarrays is small. In 
general, there are two microarray-based methods for SNPs genotyping. One is arraying thousands of 
short oligonucleotides to substrates for detection of thousands upon thousands of possible SNPs in 
target DNA [8-10]. This method is suited for genotyping a large amount of markers in a limited 
number of individuals. In many cases, association analysis needs several markers of interest genes for 
large samples, so the first kind of microarray is not adapted to it. The other kind of microarray 
approach involves arraying samples DNA including amplified PCR products to substrates to detect 
SNPs in a large number of samples [11]. Our lab has successfully developed 3-dimentional (3-D) 
polyacrylamide gel-based microarray hybridized with dual-color fluorescent probes to genotype 
several SNPs in hundreds and thousands of samples, which belongs to the second kind microarray for 
SNP genotyping [12,13]. 
Many genetic variants and environmental exposures can influence the occurrence and progression 
of psychiatric disorders, including autism [14]. Autism is a permanent developmental disorder 
characterized by marked deficits in communication and social interaction skills, language impairment, 
and abnormal behavior. After decades of research, the cause of autism is still unknown. Several studies 
have provided evidence suggesting that autism is a pathophysiological process arising from the 
interaction of an early environmental insult with a genetic predisposition for the disease [15]. Family 
and twin studies have produced the evidence for a higher genetic risk for autism in siblings of autistic 
probands than in the general population, providing additional support for the hypothesis of the 
importance of genetic risk factors in autism [16]. Although there has been a significant increase in 
autism genetics research recently, validated susceptibility genes for autism have yet to be identified. 
The identification of autism-susceptibility genes will not only assist in the identification and/or 
development of better medications that can help improve the health and neurodevelopment of children 
with autism, but will also allow for better perinatal diagnosis.  Int. J. Mol. Sci. 2009, 10                 
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Brain-derived neurotrophic factor (BDNF), a small dimeric protein and a member of the 
neurotrophic factor family, is expressed widely throughout the mammalian brain [17]. BDNF is 
involved in the survival and differentiation of dopaminergic neurons in the developing brain, and plays 
an important role in the formation and plasticity of synaptic connections [18]. BDNF is also trophic for 
serotonergic neurons, and abnormalities in serotonin levels are the most common biochemical findings 
in autism [19]. In this study, we examined the SNP- and haplotypic-association of BDNF gene with 
autism in case-control study. Four SNPs (rs988748, rs2049046, C270T and rs6265) were selected for 
association study. 
 
2. Results and Discussion 
 
2.1. Gel-based microarray for genotyping  
 
Four SNPs (rs988748, rs2049046, C270T and rs6265) of BDNF gene were selected for our 
association study. Genotyping was acquired by three-dimentional (3-D) polyacrylamide gel-based 
microarray hybridized with dual-color fluorescent probes. Schematic outline of gel-immobilization 
microarray approach for high-throughput genotyping is shown in Figure1. The whole SNP detection 
system mainly involves five steps: polymerase chain reaction (PCR), immobilization of PCR products, 
hybridization, electrophoresis of microarray and scanning for genotyping. 
 
Figure 1. Schematic outline of gel-immobilization microarray approach for SNP 
genotyping in a large number of samples. The platform for SNP genotyping mainly 
involves five steps: polymerase chain reaction (PCR), immobilization of PCR products, 
hybridization, electrophoresis of microarray and scanning for genotyping. 
 
 
After overlapping Cy3 and Cy5 image, a variety of different fluorescent signals of SNPs loci should 
be shown for three genotypes. The homozygous wild type yielded a strongly fluorescing Cy3 spots 
(green fluorescence). The homozygous mutant type yielded a strongly fluorescing Cy5 spots (red 
fluorescence). As the heterozygote yielded both fluorescing Cy3 and Cy5 spots, a strongly ‘yellow’ 
fluorescence was shown. The scan images of the four SNPs for part of samples are shown in Figure 2. Int. J. Mol. Sci. 2009, 10                 
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Figure 2. Hybridized image of four SNPs of BDNF gene for part of samples. 
 
 
 
 
 
 
 
 
 
 
 
 
The images acquired by the confocal scanner which was fitted with filters for Cy3 and Cy5. The 
green spots indicate wild homozygous, the red spots indicate mutant homozygous, and the yellow 
spots indicate heterozygote. (A) scan image of rs988748, (B) scan image of rs2049046, (C) scan 
image of C270T, (D) scan image of rs6265. 
 
Our lab has successfully developed dual-color hybridization based microarray to genotype several 
SNPs in hundreds and thousands of samples. The method was based on immobilizing amino modified 
PCR products onto a poly-L-lysine coated glass slides to fabricate a microarray, which was then 
interrogated by hybridization with dual-color probes to determine the SNP genotype of each sample 
[11]. Three genotypes could be analyzed easily according to green, red and yellow colors. It was 
confirmed that dual-color fluorescence hybridization was an accurate method for SNPs genotyping. 
Because of the low immobilization efficiency of nucleic acids in two-dimensional (2-D) substrates, 
purification and concentration of PCR products by commercial purification cartridges was required to 
achieve high quantity in microarray spotting. Generally 200 μL of PCR products was needed, which 
were concentrated to 20 μL for genotyping. The purification steps increase not only the cost and labor 
needed, but also the risk of introducing contamination, especially in the process of purifying large 
amounts of PCR products for a large number of samples. In order to overcome the limitations of the 
planar microarray format, polyacrylamide gel-based microarray technology was developed [12]. As 
the polyacrylamide gel-based microarray has long branching capillaries that can bind DNA molecules 
on to solid 3-D structure substrate, this substrate can provide surfaces with very high probe density 
(200 fmol/mm
2) [20], which is several hundred fold larger than that of 2-D substrate. Only 20 μL PCR 
reaction volume is needed for genotyping, and concentration and purification of PCR products can be 
abandoned. On the other hand, the gel-based microarray is porous, which can offer liquid-liquid 
environment for hybridization like in solution, so the efficiency of hybridization is enhanced much 
more than that of 2-D microarray.  
Acrylamide-modified nucleic acids polymerized with acrylamide monomers to fabricate gel-based 
microarray was first described by Rehman et al. [20]. The gel-based microarray has many advantages, 
but the method has not been accepted and used broadly for many years. The main problem of this 
method is that it was unable to control the polymerization process, so that the viscosity of   
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the prepolymer solution and the concentration of the probes will change during the spotting, as the 
polymerization of prepolymer was initiated immediately after mixing. Thus it was difficult to spot the 
mixed prepolymers homogeneously onto the slide to acquire a large scale microarray. According to  
the polymerization mechanism, the prepolymer does not polymerize immediately at room temperature 
without TEMED, so we modified Rehman’s method by controlling the polymerization to prepare the 
sample microarray. Excluding TEMED, acrylamide modified PCR products were mixed with 
acrylamide monomers, glycerol, 1XTBE, APS into prepolymer mixture. The prepolymer mixture was 
chemically stable, both the concentration of the nucleic acid and the viscosity of the solution remained 
unchanged for a long time. Thus, the mixture could be spotted stably in a period long enough for 
forming homogeneous microarray spots. After spotting, the prepared slides were placed in a vacuum 
chamber with TEMED under reduced pressure, so that TEMED was vaporized and diffused into the 
gel spots to induce polymerization. With this improvement, the polymerization process could be 
controlled, and a high quality gel-based DNA microarray could be fabricated.  
Though many advantages had the polyacrylamide gel-based microarray, there were still some 
drawbacks for wide application, especially porous structure intensively adsorbed the labeled nucleic 
acid, which could lead to high backgrounds. Removing the adsorbed nucleotide and the other 
nonspecific bindings by the conventional washing steps was not easy, especially for removing single 
base mismatched probes. In our method, electrophoresis of the slides was used instead of the 
conventional washing procedure in the post-hybridization process [12]. During electrophoresis, the 
hybrids (the dual-spiral structures formed in hybridization) would be unchained when probes were 
continuously removed. In this case, not only the non-specific binding probes, but also the probes 
participating in hybridization would be removed. The stability of the perfectly matched hybrid is 
higher than that of the mismatched one, so the fluorescence signal change of the hybrid with 
mismatched target is faster than that of matched one. Under optimal conditions, such as the optimized 
electrophoresis temperature, voltage and current, only the perfectly matched sequences had the distinct 
hybridization signals. 
 
2.2. Association study 
 
A total of 124 autism patients and 120 matched controls were involved in the association study. 
The age and sex distributions for the autism and control populations were similar (p > 0.05). The 
genotypes and the allele distributions and Hardy–Weinberg equilibrium tests for the four BDNF 
polymorphisms in the autism patients and controls are presented in Table 1. No polymorphism showed 
evidence of deviation from the expected values at the Hardy–Weinberg equilibrium test for either 
cases or controls (p > 0.05). Among the four BDNF polymorphisms, only C270T showed significant 
differences in the frequency of the allele (p = 0.005) and genotype (p = 0.020) between autism patients 
and healthy controls (Table 1). The four markers were found to be in strong LD to each other both in 
the patient group (D’  >  0.7) and the control group (D’  >  0.7). The results of global case-control 
haplotype analysis and comparisons of individual haplotypes between groups are presented in Table 2. 
Haplotype was organized from 5’ to 3’: rs988748, rs2049046, C270T, rs6265. Only haplotypes with 
frequency > 0.03% were considered in analysis. Global case-control haplotype analysis showed that 
there was significant difference in haplotype distribution (χ
2 = 28.19，p = 3.44e-005). Individual Int. J. Mol. Sci. 2009, 10                 
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haplotype analysis showed that the frequencies of three haplotypes (CTTG, CACA and GTCG) had 
significant difference between groups (p < 0.05). 
 
Table 1. HWE test, genotype distribution and allele frequencies of the BDNF genetic 
polymorphisms for autism (n = 124) and controls (n = 120). 
SNP Group  HWE  Genotype（） frequency %   p value  Allele (frequency %)  p value  OR
a  95%CI
b 
rs988748 
  CC CG  GG   C  G      
Autism 0.175 33(0.266) 69(0.556)  22(0.177) 0.228 135(0.544) 113(0.456) 0.807 1.045 0.732~1.492 
Control 0.293  37(0.308) 54(0.450) 29(0.242)    128(0.533) 112(0.467)       
rs2049046 
  AA AT TT   A  T      
Autism 0.208 28(0.226) 69(0.556)  27(0.218) 0.191 125(0.504) 123(0.496) 0.710 0.935 0.655~1.334 
Control 0.207  36(0.300) 53(0.442) 31(0.258)    125(0.521) 115(0.479)       
C270T 
  CC CT TT   C  T      
Autism 0.876  96(0.774) 26(0.210) 2(0.016)  0.020 218(0.879) 30(0.121) 0.005  0.382 0.191~0.766 
Control 0.564 108(0.900) 12(0.100) 0(0.000)    228(0.950) 12(0.050)       
rs6265 
  AA AG  GG   A  G      
Autism 0.129 22(0.177) 70(0.565)  32(0.258) 0.274 114(0.460) 134(0.540) 0.734 0.940 0.658~1.342 
Control 0.481  29(0.242) 56(0.467) 35(0.292)    114(0.475) 126(0.525)       
a: Odds Ratio. 
b: Confidence Intervals. 
 
Table 2. Inferred haplotype frequency in BDNF gene and haplotype comparison between 
autism patients and controls. 
Haplotype case  control  chi  p value  OR[95%CI] 
G A C A  96.09(0.387)  107.30(0.447)  1.300  0.2543281  0.808 [0.560~1.166] 
C A C G  9.21(0.037)  13.51(0.056)  0.901  0.342672  0.696 [0.293~1.650] 
C T C G  88.96(0.359)  104.14(0.434)  2.296  0.129761  0.752 [0.520~1.088] 
C T T G  21.99(0.089)  7.81(0.033)  7.056  0.007923  2.972 [1.286~6.868] 
C A C A  10.26(0.041)  0.00(0.000)  10.382  0.001281  — 
G T C G  8.58(0.035)  0.00(0.000)  8.767  0.003082   
Global result: Total control = 240.0,  total case = 248.0, χ2 = 28.194, df = 5, p = 3.44e-005 
Haplotype is organized from 5’ to 3’: rs988748, rs2049046, C270T and rs6265. Only haplotypes with frequency  
> 0.03% are listed in this table. 
 
In the brain, BDNF has been implicated in development, neural regeneration, synaptic transmission, 
synaptic plasticity and neurogenesis [21,22]. Elevated BDNF expression has been observed in the 
brain [23], blood [24] and serum [25,26] of autistic individuals, compared to healthy controls. Another 
line of evidence concerned that BDNF had a possible role in the pathogenesis of autism through its 
neurotrophic effects on the serotonergic system. The serotonergic system has been found to be Int. J. Mol. Sci. 2009, 10                 
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developmentally dysregulated in autism, and BDNF has been confirmed to play a critical role in the 
serotonergic function [27,28]. BDNF has been implicated having correlation with some psychiatric 
disorders, including depression [29], obsessive compulsive disorder [30], attention deficit 
hyperactivity disorder (ADHD) [31,32], and anxiety-related personality traits [33]. In the present study, 
we investigated whether a relationship existed between genetic variants of BDNF gene and autism.  
The human BDNF gene is located on the short arm of chromosome 11 at the boundary of 11p13 
and 11p14 [34]. Four SNPs within the BDNF gene were selected for association study, which had been 
confirmed to be associated with other psychiatric disorders, such as schizophrenia, Alzheimer’s 
disease, ADHD and so on. We would like to know whether the four SNPs had any relationship with 
autism too. Among the four SNPs, only C270T showed significant differences in the frequency of the 
allele and genotype between patients and controls. Increased transmission of the T allele of   
C270T polymorphism was found in autism samples (autism, 12.1%, control, 5.0%). The C270T 
polymorphism is located in the 5’-noncoding region of intron 1 and maybe influences changes in 
BDNF expression [35]. Further studies are needed to determine whether the T allele is correlated with 
elevated BDNF expression in autistic patients. 
There was no significant difference of rs988748, rs2049046 and rs6265 polymorphisms between 
the patients and controls. The rs988748 and rs2049046 polymorphisms are located in the promoter 
region. The SNP rs6265 has been identified at nucleotide 196 within the 5’ precusor peptide 
(proBDNF) sequence that causes an amino acid substitution of valine to methionine at codon 66 
(Val66Met) [36]. The rs6265 polymorphism has been reported to be associated with obsessive 
compulsive disorder [30], attention deficit hyperactivity disorder (ADHD) [31,32], anxiety-related 
personality traits [33] and other childhood-onset mood disorder [37]. This SNP has also been 
suggested to have a role in the hippocampal and prefrontal cortex functions involved in human 
memory and learning [38,39]. However, we did not observe significant association of rs6265 
polymorphism with autism. It is suggested that further study is needed in a larger sample. 
We also found significant difference of global haplotype and three individual haplotype in case-
control study. Increased transmission of the haplotypes CTTG, CACA, GTCG were showed in the 
autism group. As these haplotypes, especially CACA (4.1%) and GTCG (3.5%) were also rare in the 
patients group, it was hard to confirm that the increased transmission of the haplotypes were associated 
with autism. A similar study by Nishimura had been done about two years ago. Twenty-five SNPs 
were selected for analysis in trio families of the Caucasian population. They found some haplotype 
blocks show significant associations in the autism, but didn’t find significant associations from any 
single SNP [19]. Our findings were based on case-control study in Chinese population. Three SNPs 
were same to Nishimura’s study, except C270T polymorphism. Yet only C270T show significant 
association in the autism. 
If BDNF is an uncommon disease locus or one with a small effect, our power to detect a gene 
would be reduced. A further study in a larger sample is needed to fully resolve the possible 
involvement of the genetic variants of the BDNF gene in autism. Int. J. Mol. Sci. 2009, 10                 
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3. Experimental Section 
 
3.1. Subjects 
 
In the present study, a total of 124 Chinese Han autism patients were recruited at Child Mental 
Health Research Center of Nanjing Brain Hospital, Nanjing Medical University, P.R. China. The 
diagnosis of the autistic disorder was based on the criteria of the Fourth Edition of Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV), the Autism Diagnostic Inventory-Revised (ADI-R), 
and the Childhood Autism Rating Scale (CARS). In these patients, 107 (86.3%) were male and 17 
(13.7%) were female, and the mean age was 5.36 and 4.57 years. A group of 120 control subjects 
matched age and sex were recruited from community. None of control subjects had a history of 
diagnosed neurological disorder or genetic, major medical condition. All participants signed a written 
informed consent and all research procedures were approved by the Ethics Committee of Nanjing   
Brain Hospital. 
 
3.2. Genotyping 
 
The genomic DNA was extracted from the peripheral blood leukocytes using an improved KI 
salting-out procedure. Four SNPs (rs988748, rs2049046, C270T and rs6265) of BDNF gene were 
selected for association study. Genotyping was acquired by 3-dimentional (3-D) polyacrylamide gel-
based microarray hybridized with dual-color fluorescent probes. Schematic outline of gel-
immobilization microarray approach for high-throughput genotyping is shown in Figure 1. The whole 
SNP detection system mainly involves five steps: polymerase chain reaction (PCR), immobilization of 
PCR products, hybridization, electrophoresis of microarray and scanning for genotyping. The details 
of each step are explained as follows. 
 
3.2.1. PCR Amplification 
 
PCR primers were designed using primer Premier 5.0 software based on published DNA sequence. 
The primers were synthesized and HPLC purified in TaKaRa Company (P.R. China). All reverse 
primers were modified with acrylamide group at 5’-terminal in order to covalently attach with the 
polyacrylamide gel. The sequences of all the primers and the predicted size of the PCR amplified 
fragments are shown in Table 3. Amplification was carried out in a final volume of 2 μL, consisting of 
1.0 × PCR buffer (which contain 10 mM Tris-HCl, 50 mM KCl), 1.2 mM MgCl2, 200 μM dNTPs,  
0.5 μM of each primer, 1 U Taq polymerase and 50 ng of genomic DNA. The profile consisted of an 
initial melting
 step of 4 min at 94 °C, followed by 35 cycles of 30 seconds at
 94 °C, 30 seconds at  
57 °C, and 30 seconds at 72 °C, with
 a final extension step of 5 min at 72 °C. After PCR amplification, 
PCR products were processed by ethanol precipitation. 
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Table 3. Primer sequence and probe sequence of four SNPs of BDNF gene. 
SNP ID  Primer sequence (5’-3’) 
Fragment 
size (bp) 
Probe sequence 
rs988748 
 
F: 5’-TAGGGTTCCTCCAGTCCTTT 
R: ’-Acryl-CAGCACAGATGGCAGAGTTTA
250 
5’-Cy3-GGGTCTCTGGGGT 
5’-Cy5-GGGTCTGTGGGGT 
rs2049046 
 
F: 5’-CAGGAGGAGGGACCTTCATT 
R: 5’-Acryl-AGCCTTTCGGGTTCTCATTT 
293 
5’-Cy3-CCAGGGACTCCAA 
5’-Cy5-CCAGGGTCTCCAA 
C270T 
 
F: 5’-CAGAGGAGCCAGCCCGGTGCG 
R: 5’-Acryl-CTCCTGCACCAAGCCCCATTC 
213 
5’-Cy3-CTCCACCTCCTGC 
5’-Cy5-CTCCACTTCCTGC 
rs6265 
 
F: 5’-AAACATCCGAGGACAAGGTG 
R: 5’-Acryl-AGAAGAGGAGGCTCCAAAGG 
246 
5’-Cy3-GAACACATGATAG 
5’-Cy5-GAACACGTGATAG 
 
3.2.2. Immobilization of PCR products 
 
Acryl-modified slides were prepared in advance. Glass slides were cleaned by soaking in 10% 
aqueous nitric acid for 2 h. Slides were then rinsed with water and acetone and air dried. The cleaned 
slides were soaked in 10% 3-methacryloxypropyltrimethoxy silane (Sigma Corporation, USA) in 
acetone for 1 h, and were washed in acetone and air dried for use [20]. 
Acrylamide-modified PCR products were dissolved with the solutions which contained 3% 
acrylamide monomer (29:1 acrylamide:bis-acrylamide), 30% glycerol, 1% APS, and then were spotted 
on the 3-methacryloxypropyltrimethoxy silane modified glass slides using a microarrayer (Captial 
Biochip Corporation, P.R. China). After spotting, the slide was placed into a humid sealed chamber in 
which a well containing TEMED was deposited in advance. The pressure in the sealed chamber was 
reduced to about 1,000 Pascal (Pa), and this pressure was maintained for 20 minutes at room 
temperature. Under this pressure, TEMED was vaporized and diffused into the spots and onto the slide 
surfaces to induce the copolymerization between acrylamide groups and acryl groups. Following the 
attachment, the slide was incubated in 0.1 M NaOH for electrophoresis eight min to obtain single 
stranded DNA (ssDNA) for hybridization and then incubated in 1XTBE for electrophoresis eight 
minutes for removing NaOH [12]. The slides were prepared for hybridization. 
 
3.2.3. Hybridization 
 
For every SNP locus, a pair of probes were designed which could be matched with polymorphism 
part of the targets and labeled with the Cy3 or Cy5 respectively (Figure 3). The length of probes 
ranged from 13-15nt and the Tm value were adjusted within the range of 37-42 °C. The sequences of 
the probes were shown in Table1. For every SNP genotyping, a pair of labeled probes were mixed in 
equimolar amounts and suspended in unihybridization solution (3:1 dilution) with the finial 
concentration of 2μM. Hybridization was performed in a moist chamber at 37 °C for 2-4 hours.  
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Figure 3. A schematic outline of SNP genotyping approach using dual-color fluorescence 
hybridization. 
 
(A) homozygous wild type; (B) heterozygote type; (C) homozygous mutant type. 
 
3.2.4. Post-hybridization 
 
After hybridization, the slides were subjected to electrophoresis (DYY-6C model electrophoresis 
cell, Beijing Liuyi Instrument Factory, P.R. China) under 2 V/cm for eight min in 1×TBE buffer at  
4 ºC. After electrophoresis was completed, the slide was rinsed in water and air dried. 
 
3.2.5. Scanning and genotyping 
 
The hybridization slides were scanned at 70% laser power and 65% PMT Gain with confocal 
scanner (Luxscan-10K/A, CapitalBio Company, P.R. China) after the above treatment. The scanner 
was fitted with filters for Cy3 and Cy5. Images were analyzed with QuantArray software.  
 
3.3. Statistical analysis 
 
Hardy Weinberg equilibrium (HWE), linkage disequilibrium (LD), haplotype construction and 
comparison in allele, genotype, and haplotype distribution between patients and controls were tested 
by SHEsis program (http://analysis.bio-x.cn/myAnalysis.php) [40]. The statistical significance was 
defined by p < 0.05. The option ‘drop rare haplotypes’ was used to restrict the analysis of haplotypes 
with a frequency < 3%. 
 
4. Conclusions 
 
It is concluded that the polyacrylamide gel-based microarray combined with dual-color 
hybridization is a rapid, simple and high-throughput method for SNPs genotyping, and has been 
successfully used for association study of BDNF gene with autism. The present study suggests that 
BDNF may play a role in the pathogenesis of autism through its neurotrophic effects on central 
nervous system. However, further studies including replication of these findings in a large sample, the 
association of polymorphisms with BDNF expression and the functional impact of BDNF in autism  
are warranted. Int. J. Mol. Sci. 2009, 10                 
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